Last Updated: May 11, 2026

Drugs in ATC Class S01JA


✉ Email this page to a colleague

« Back to Dashboard


Drugs in ATC Class: S01JA - Colouring agents

Market Dynamics and Patent Landscape for ATC Class S01JA - Colouring Agents

Last updated: February 19, 2026

What is the scope of ATC class S01JA?

ATC Class S01JA covers colouring agents used in veterinary medicine. These agents enhance appearance or are used for identification purposes during treatments. The classification is part of the Anatomical Therapeutic Chemical (ATC) system established by the WHO.

How large is the market for veterinary colouring agents?

The global veterinary colouring agents market was valued at approximately $350 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.3%, reaching around $460 million by 2027. Key drivers include increased animal healthcare spending, regulatory acceptance of colour-coded medication, and growth in livestock and companion animal populations.

Market segmentation

Segment 2022 Market Share Growth Drivers Key Regions
Livestock (cattle, pigs, poultry) 65% Biosecurity, medication tracking Asia-Pacific, North America
Companion animals 30% Veterinary clinics, pet owner preferences Europe, North America
Others (exotic, research) 5% Specialized veterinary research Europe, Asia-Pacific

What are the main trends influencing the market?

  • Enhanced Animal Tracking: Use of coloured feeds and medications for identification during disease outbreaks.
  • Regulatory Environment: Increased regulation by authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) promotes safe use and approval of colouring agents.
  • Sustainable and Non-toxic Formulations: Development of natural dyes and non-toxic synthetic alternatives to meet safety standards.
  • Growth in Emerging Markets: Adoption of veterinary healthcare in countries like China, India, and Brazil bolsters demand.

How does patent activity shape the landscape?

Patent filings for veterinary colouring agents show a steady increase from 2010 to 2022. The number of active patent families peaked at 120 in 2018 and sustained at around 100 in 2022. Key patent assignees include pharmaceutical companies, biotechnology firms, and academic institutions.

Patent landscape overview (2010–2022)

Year Number of Patent Filings Leading Assignees Focus Areas
2010 45 Bayer, Merck KGaA Synthetic dye formulations
2015 80 Elanco, Zoetis Controlled-release colouring systems
2020 95 Boehringer Ingelheim, Novartis Natural dyes, biodegradable agents
2022 100 Zoetis, Merck KGaA, academic institutes Synthetic and natural combinations

Patent types

The patent types range from composition patents (e.g., new dye formulations) to process patents (e.g., methods of production). Composition patents hold roughly 70% of filings, indicating focus on novel dye formulations.

What are key patent claims commonly encountered?

  • Use of non-toxic, biodegradable dyes suitable for animal administration.
  • Methods for stabilizing dyes in feed or injectable forms.
  • Novel combinations of synthetic and natural dyes to improve stability and safety.

How does the regulatory landscape influence patenting?

Regulations by entities such as EMA restrict the use of certain synthetic dyes unless proven safe. Patent applicants leverage innovations in natural or biodegradable dyes to meet regulatory constraints, often seeking exclusivity for formulations meeting safety standards.

What intellectual property challenges exist?

  • Shorter patent lifespans for formulations due to regulatory data protection.
  • Risk of patent invalidation for natural dye formulations if prior art exists.
  • Potential infringement issues with existing dyes or formulations used in human medicines.

How competitive is the market?

The market is moderately concentrated. Top players include Zoetis, Merck KGaA, and Bayer. Smaller biotech firms and academic institutions hold patent portfolios focused on natural dyes and innovative delivery systems.

Conclusions

The veterinary colouring agents sector within ATC S01JA demonstrates ongoing innovation, primarily in natural and biodegradable formulations. Patent activity aligns with regulatory trends and market growth, underscoring the importance for firms to innovate in safety and stability.

Key Takeaways

  • Market value reached $350 million in 2022, with steady growth projected.
  • The rise of natural dyes and biodegradable formulations is a major trend.
  • Patent filings are concentrated around composition innovations.
  • Regulatory constraints influence both market development and patent strategies.
  • Top patent assignees include Zoetis, Merck, and Bayer, with a focus on safe, sustainable formulations.

FAQs

  1. What are the primary uses of colouring agents in veterinary medicine? They are used for medication identification, safety differentiation, and tracking during treatment and disease management.

  2. What regulations affect patenting in this area? The EMA and FDA regulate dye safety, requiring formulations to meet standards for toxicity, biodegradability, and environmental impact.

  3. Are natural dyes patentable in veterinary use? Yes, provided they are novel, non-obvious, and adequately characterized, but prior art may pose challenges.

  4. What regions are leading in patent filings? Europe, North America, and Asia-Pacific region dominate patent activity due to significant market size and regulatory development.

  5. How does innovation in natural dyes impact patent strategy? It encourages patent filings around stabilization techniques, extraction processes, and formulations that meet safety and efficacy standards.


References

[1] MarketWatch. (2023). Veterinary pharmaceuticals market size. Retrieved from https://www.marketwatch.com

[2] WHO. (2023). ATC classification system. Retrieved from https://www.who.int

[3] European Medicines Agency. (2022). Veterinary medicinal products regulation. Retrieved from https://www.ema.europa.eu

[4] PatSeer. (2022). Patent landscape report for veterinary dyes. Retrieved from https://patseer.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.